Last reviewed · How we verify

efanesoctacog alpha — Competitive Intelligence Brief

efanesoctacog alpha (efanesoctacog alpha) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant fusion protein / Coagulation factor bypass agent. Area: Hematology.

marketed Recombinant fusion protein / Coagulation factor bypass agent Factor IXa and Factor X (intrinsic tenase complex) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

efanesoctacog alpha (efanesoctacog alpha) — Versiti Blood Health. Efanesoctacog alpha is a recombinant fusion protein that bridges Factor IXa and Factor X to restore the intrinsic tenase complex activity in patients with hemophilia B.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
efanesoctacog alpha TARGET efanesoctacog alpha Versiti Blood Health marketed Recombinant fusion protein / Coagulation factor bypass agent Factor IXa and Factor X (intrinsic tenase complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant fusion protein / Coagulation factor bypass agent class)

  1. Versiti Blood Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). efanesoctacog alpha — Competitive Intelligence Brief. https://druglandscape.com/ci/efanesoctacog-alpha. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: